非酒精性脂肪性肝病与肝硬化

doi:10.3969/j.issn.1672-5069.2016.02.003

Abstract

Ma Zhenzeng, Lu Lungen. Nonalcoholic fatty liver disease and liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 135-138.

[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.中国非酒精性脂肪性肝病诊疗指南.中国医学前沿杂志（电子版）, 2012, 4（7）:4-10.
[2] Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fattyliver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther ,2011, 34:274-285.
[3] de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol, 2008, 48 （Suppl 1）:5104-5112.
[4] Wang FS,Fan JG,Zhang Z,et al. The global burden of liver disease:The major impact of China.Hepatology, 2014, 60:2099-2108.
[5] Amarapurkar DN, Hashimoto E, Lesmana LA, et al. Asia-Pacific Working Party for NAFLD. Howcommon is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences J Gastroenterol Hepatol, 2007,22:788-793.
[6] Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology, 2004, 40:185-194.
[7] Fujii H, Kawada N. Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol, 2012, 47:215-225.
[8] Chalasani N, Zobair Younossi F, Joel E. et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 2012, 55（6）：2005-2023.
[9] Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology, 2005, 129: 113-121.
[10] Musso G, Gambino R, Cassader M,et al. Meta-analysis:natural history of non-alcoholic fatty liver disease （NAFLD）and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med , 2011, 43: 617-649.
[11] Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up ofpatients with NAFLD and elevated liver enzymes. Hepatology, 2006, 44: 865-873.
[12] White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol, 2012, 10: 1342-1359.
[13] Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol, 2013, 10:656-665.
[14] Agrawal S, Duseja AK. Non-alcoholic fatty liver disease: East versus west. J Clin Experiment Hepatol, 2012, 2 （2）: 122-134.
[15] Nayak NC, Vasdev N, Saigal S, et al. End-stage nonalcoholicfatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explant livers in a living donor liver transplant program. Hum Pathol, 2010, 41:425-430.
[16] Michitaka K, Nishiguchi S, Aoyagi Y, et al.Japan etiology of liver cirrhosis study group. Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol, 2010, 45:86-94.
[17] Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol, 2014, 28 : 637-653.
[18] Vlad R, Stefano B, Helena H. CA position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol , 2010 ,53 :372-384.
[19] Jessica KD, Quentin MA, Stuart MP. Non-alcoholic fatty liver disease:a practical approach to diagnosis and staging. Frontl Gastroenterol, 2014, 5:211-218.
[20] Schwenzer NF, Springer F, Schraml C, et al. Non-invasiveassessment and quantification of liver steatosis by ultrasound,computed tomography and magnetic resonance. J Hepatol,2009, 51:433-445.
[21] Angulo P, Hui J, Marchesini G, et al. The NAFLD fibrosisscore: a noninvasive system that identifies liver fibrosis inpatients with NAFLD. Hepatology, 2007, 45:847-854.
[22] Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosisand cirrhosis using liver stiffness measurement in nonalcoholicfatty liver disease. Hepatology, 2010,51:454-462.
[23] Yoneda M, Suzuki K, Kato S, et al. Nonalcoholic fatty liverdisease: US-based acoustic radiation force impulse elastography.Radiology,2010,256:640-647.
[24] Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers.Hepatology, 2008,47:455-460.
[25] Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology, 2006, 44:27-33.

Nonalcoholic fatty liver disease and liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Ren Yufei, Chen Xiaoqing, Kong Weizong, et al.. Effect of salvianolic acid B on autophagy in nonalcoholic fatty liver disease cell model in vitro [J]. Journal of Practical Hepatology, 2019, 22(6): 804-807.
[3]	Li Yingyi, Guo Cuifen, Zhang Ruinan, et al.. Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 848-851.
[4]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[5]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[6]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[7]	Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.
[8]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[9]	Ba Zhengwu, Li Hailong, Yang Hui. Quantitative evaluation of hepatic function by EDCT in patients with Budd-Chiari syndrome before and after TIPS [J]. Journal of Practical Hepatology, 2019, 22(5): 680-683.
[10]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[11]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[12]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[13]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[14]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[15]	Chen Shan, Zhuang Huashuai, Xing Yixi, et al. Preventive application of meropenem in patients with liver cirrhosis complicated by upper gastrointestinal bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 704-707.